生物製剤に抵抗性の強直性脊椎関節炎におけるウパダシチニブの疾患活動性, 疼痛, 倦怠感, 機能, 健康関連QOL, 労働生産性に対する効果
Rheumatol Ther 2023; 10:679–91 doi 10.1007/s40744-023-00536-2
Upadacitinib significantly improved patient-reported outcomes in AxSpA patients with bDMARD-IR after 14 Weeks of treatment. There were notable improvements in disease activity, pain, fatigue, function, HRQoL, and work productivity.
Navarro-Compán, et al. report results from SELECT-AXIS 2, a phase 3, randomised, double-blind, parallel-group, placebo-controlled trial. This study shows that upadacitinib is a suitable oral drug for bDMARD-IR AxSpA patients.
Keywords:
